PT1404357E - Hormona antagonista de libertação de gonadotrofina em concentrações de gel - Google Patents
Hormona antagonista de libertação de gonadotrofina em concentrações de gel Download PDFInfo
- Publication number
- PT1404357E PT1404357E PT02749000T PT02749000T PT1404357E PT 1404357 E PT1404357 E PT 1404357E PT 02749000 T PT02749000 T PT 02749000T PT 02749000 T PT02749000 T PT 02749000T PT 1404357 E PT1404357 E PT 1404357E
- Authority
- PT
- Portugal
- Prior art keywords
- peptide
- concentration
- solution
- gel
- composition according
- Prior art date
Links
- 239000002474 gonadorelin antagonist Substances 0.000 title claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 239000008196 pharmacological composition Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 8
- 239000000243 solution Substances 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 229940011871 estrogen Drugs 0.000 claims 2
- 239000000262 estrogen Substances 0.000 claims 2
- 230000004720 fertilization Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 229940124558 contraceptive agent Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- -1 salt hydrochloride Chemical class 0.000 claims 1
- 239000005557 antagonist Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 3
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 230000002483 superagonistic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 102000008238 LHRH Receptors Human genes 0.000 description 1
- 108010021290 LHRH Receptors Proteins 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004185 hypothalamic-pituitary-gonadal axis Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000006155 precocious puberty Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0117057.0A GB0117057D0 (en) | 2001-07-12 | 2001-07-12 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1404357E true PT1404357E (pt) | 2010-03-16 |
Family
ID=9918396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT02749000T PT1404357E (pt) | 2001-07-12 | 2002-07-08 | Hormona antagonista de libertação de gonadotrofina em concentrações de gel |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20050245455A1 (enExample) |
| EP (1) | EP1404357B1 (enExample) |
| JP (1) | JP4845166B2 (enExample) |
| AR (1) | AR036337A1 (enExample) |
| AT (1) | ATE452648T1 (enExample) |
| DE (1) | DE60234831D1 (enExample) |
| DK (1) | DK1404357T3 (enExample) |
| ES (1) | ES2338217T3 (enExample) |
| GB (1) | GB0117057D0 (enExample) |
| MY (1) | MY139203A (enExample) |
| PT (1) | PT1404357E (enExample) |
| UY (1) | UY27378A1 (enExample) |
| WO (1) | WO2003006049A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| NZ538928A (en) | 2002-09-27 | 2006-10-27 | Zentaris Gmbh | Administration form for pharmaceutically active peptides with sustained release of active ingredient, and method for the production thereof |
| EP3025722B1 (en) | 2003-10-03 | 2020-05-27 | Thorn BioScience, LLC | Process for the synchronization of ovulation for timed breeding without heat detection |
| GB0511269D0 (en) | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
| EP2120859B1 (en) * | 2006-12-21 | 2013-11-20 | Stryker Corporation | Sustained-release formulations comprising bmp-7 crystals |
| TWI442932B (zh) | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
| PL2421545T3 (pl) | 2009-04-23 | 2018-05-30 | Jbs United Animal Health Ii Llc | Sposób i kompozycja do synchronizacji czasu inseminacji |
| AU2010243273B2 (en) * | 2009-05-01 | 2016-06-16 | Ferring B.V. | Composition for the treatment of prostate cancer |
| JO3550B1 (ar) * | 2009-05-01 | 2020-07-05 | Ferring Int Center Sa | مركب لمعالجة سرطان البروستاتا |
| TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| HRP20161746T1 (hr) | 2010-10-27 | 2017-02-10 | Ferring B.V. | Postupak za proizvodnju degareliksa i njegovih međuprodukata |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| WO2013104745A1 (en) * | 2012-01-13 | 2013-07-18 | Ferring Bv | Pharmaceutical composition |
| FI4512390T1 (fi) | 2012-06-01 | 2025-08-01 | Ferring Bv | Degareliksin valmistaminen |
| ITMI20121638A1 (it) * | 2012-10-02 | 2014-04-03 | Marco Sbracia | Utilizzo di degarelix nel trattamento dell'endometriosi e di patologie ad essa correlate |
| RU2015125549A (ru) | 2012-11-28 | 2017-01-11 | ДжейБиЭс Юнайтид Энимал Хэлс II ЛЛК | Способ для синхронизации времени осеменения молодых свиней |
| US10681261B2 (en) * | 2012-11-30 | 2020-06-09 | 3I Avi, Llc | Inspection system |
| TW201625218A (zh) * | 2014-04-18 | 2016-07-16 | Ｊｂｓ聯合動物保健有限責任公司 | 製造含ｇｎｒｈ凝膠之方法 |
| BR112019014192A2 (pt) * | 2017-01-30 | 2020-02-11 | Antev Limited | Composição compreendendo pelo menos um antagonista de gnrh |
| WO2019110688A1 (en) | 2017-12-05 | 2019-06-13 | Ferring B.V. | A composition comprising degarelix for use in the treatment of breast cancer |
| EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US200486A (en) * | 1878-02-19 | Improvement in apparatus for attaching harness to the shafts | ||
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| ES2052488T3 (es) * | 1991-04-25 | 1997-01-01 | Romano Deghenghi | Peptidos antagonistas de la hormona de liberacion de la hormona luteinizante. |
| SI9300468A (en) * | 1992-10-14 | 1994-06-30 | Hoffmann La Roche | Injectable composition for the sustained release of biologically active compounds |
| US5506207A (en) * | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
| US5595760A (en) * | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5860957A (en) * | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| US5925730A (en) * | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
| US5821230A (en) * | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| FR2776520B1 (fr) * | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
| US20020103131A1 (en) * | 2001-01-26 | 2002-08-01 | Jacobson Jill D. | Prevention of diabetes by administration of GnRH antagonists |
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| AR042815A1 (es) * | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| EP1891964A1 (en) * | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
| EP2257324B1 (en) * | 2008-02-11 | 2016-07-27 | Safety Syringes, Inc. | Syringe with safety needle guard and clip to prevent release of guard during reconstitution process |
| TWI442932B (zh) * | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
| AU2010243273B2 (en) * | 2009-05-01 | 2016-06-16 | Ferring B.V. | Composition for the treatment of prostate cancer |
| TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| HRP20161746T1 (hr) * | 2010-10-27 | 2017-02-10 | Ferring B.V. | Postupak za proizvodnju degareliksa i njegovih međuprodukata |
| EP2447276A1 (en) * | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| JO3755B1 (ar) * | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| EP3269368A1 (en) * | 2011-07-15 | 2018-01-17 | Ferring B.V. | Method for timing a colonoscopy wherein a picosulfate composition is administered |
-
2001
- 2001-07-12 GB GBGB0117057.0A patent/GB0117057D0/en not_active Ceased
-
2002
- 2002-07-03 MY MYPI20022511A patent/MY139203A/en unknown
- 2002-07-08 US US10/483,325 patent/US20050245455A1/en not_active Abandoned
- 2002-07-08 PT PT02749000T patent/PT1404357E/pt unknown
- 2002-07-08 EP EP02749000A patent/EP1404357B1/en not_active Expired - Lifetime
- 2002-07-08 WO PCT/GB2002/003116 patent/WO2003006049A1/en not_active Ceased
- 2002-07-08 US US10/380,623 patent/US20040038903A1/en not_active Abandoned
- 2002-07-08 AT AT02749000T patent/ATE452648T1/de active
- 2002-07-08 DE DE60234831T patent/DE60234831D1/de not_active Expired - Lifetime
- 2002-07-08 ES ES02749000T patent/ES2338217T3/es not_active Expired - Lifetime
- 2002-07-08 DK DK02749000.2T patent/DK1404357T3/da active
- 2002-07-08 JP JP2003511855A patent/JP4845166B2/ja not_active Expired - Lifetime
- 2002-07-11 UY UY27378A patent/UY27378A1/es not_active Application Discontinuation
- 2002-07-11 AR ARP020102599A patent/AR036337A1/es not_active Application Discontinuation
-
2008
- 2008-06-11 US US12/155,897 patent/US20090018085A1/en not_active Abandoned
-
2010
- 2010-10-08 US US12/901,270 patent/US20110053846A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003006049A1 (en) | 2003-01-23 |
| JP4845166B2 (ja) | 2011-12-28 |
| ES2338217T3 (es) | 2010-05-05 |
| AR036337A1 (es) | 2004-09-01 |
| DE60234831D1 (de) | 2010-02-04 |
| US20110053846A1 (en) | 2011-03-03 |
| EP1404357A1 (en) | 2004-04-07 |
| JP2005511491A (ja) | 2005-04-28 |
| GB0117057D0 (en) | 2001-09-05 |
| ATE452648T1 (de) | 2010-01-15 |
| EP1404357B1 (en) | 2009-12-23 |
| DK1404357T3 (da) | 2010-05-03 |
| US20040038903A1 (en) | 2004-02-26 |
| UY27378A1 (es) | 2003-02-28 |
| US20050245455A1 (en) | 2005-11-03 |
| MY139203A (en) | 2009-08-28 |
| US20090018085A1 (en) | 2009-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1404357E (pt) | Hormona antagonista de libertação de gonadotrofina em concentrações de gel | |
| ES2423899T3 (es) | Método para aumentar las concentraciones de testosterona y esteroides relacionados en las mujeres | |
| ES2204917T3 (es) | Formulaciones de gnrh y estrogenos sin progestogenos para tratar trastornos ginecologicos benignos. | |
| ES2248272T3 (es) | Formulacion de fulvestrant. | |
| RU99115103A (ru) | Фармацевтическая композиция для задержанной доставки пептидного соединения (варианты) и ее применение, упакованный препарат для лечения состояния, поддающегося воздействию аналога lhrh, шприц | |
| Forsling | Diurnal rhythms in neurohypophysial function | |
| TWI583391B (zh) | 用於前列腺癌之治療的組成物 | |
| Rea et al. | Testosterone maintains pituitary and serum FSH and spermatogenesis in gonadotrophin-releasing hormone antagonist-suppressed rats | |
| RU2007101304A (ru) | Модуляторы рецептора прогестерона, содержащие производные пиррол-оксиндола и применение | |
| JPH01502265A (ja) | 避妊薬用としての性ステロイド放出と組合わされた黄体形成ホルモン放出ホルモン組成物の連続放出 | |
| PT1011648E (pt) | Combinacao do inibidor de tirosina cinase e castracao quimica para tratar o cancro da prostata | |
| BR112013018951B1 (pt) | Formulações transdérmicas ou transmucosais de testosterona e seu uso e kit que compreende pelo menos um recipiente que compreende uma formulação | |
| JPH04504848A (ja) | エストロゲン感受性疾患の治療のための組合せ療法 | |
| JP2005511491A5 (enExample) | ||
| ES2247710T3 (es) | Antagonista de gonadotropina. | |
| CN1671394A (zh) | 包含雄激素性11β－卤素甾体和孕激素的组合物以及基于该组合物的雄性避孕药 | |
| ES2283446T3 (es) | Composicion de gel basada en alcohol para el tratamiento del hipogonadismo por administracion transescrotal. | |
| Brogden et al. | Goserelin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer | |
| CN1376070A (zh) | 用于治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗阻的方法 | |
| Lemay | Clinical appreciation of LHRH analogue formulations | |
| CN1498112A (zh) | 雌激素依赖性疾病的联合治疗 | |
| Gonzalez‐Barcena et al. | Inhibition of the pituitary‐gonadal axis by a single intramuscular administration of D‐Trp‐6‐LH‐RH (Decapeptyl) in a sustained‐release formulation in patients with prostatic carcinoma | |
| BR112020021565A2 (pt) | Composição para tratamento de uma ou mais doenças relacionadas com estrogênio | |
| EP3027200A1 (en) | Aqueous sustained release compositions of lhrh analogues | |
| Asch et al. | Comparison of the subcutaneous and intranasal administration of an LH-RH antagonist ([N-Ac-d-p-Cl-Phe1, 2, d-Trp3, d-Arg6, d-Ala10]-LH-RH) in the rhesus monkey |